Lexaria Bioscience LEXX
NASDAQ LEXX
$3.13 -0.09 (-2.95%)
At close: Sep 29, 2026 · 4:00 PM EDT

Lexaria Bioscience (LEXX) Research & Development (2017 - 2026)

Updated

Lexaria Bioscience's Research & Development was $970,834 in fiscal Q3 2026 (quarter ended May 31, 2026), down 64.3% from $2.72 million a year earlier but up 104.2% from the prior quarter.

Analysis

Lexaria Bioscience (LEXX) Research & Development (2017 - 2026) Analysis & Trends

On a trailing twelve-month basis, Lexaria Bioscience's Research & Development was $4 million through May 31, 2026, down 45.4% year-over-year; for FY2025 (ended Aug 31, 2025), it came in at $8.24 million, up 249.0% from FY2024.

  • Research & Development shows a five-year compound annual growth rate of 84.3% (FY2020 to FY2025).
  • In earlier fiscal years, Research & Development was $2.36 million in FY2024 (-35.6%), $3.67 million in FY2023 (+99.0%), $1.84 million in FY2022 (+45.9%) and $1.26 million in FY2021 (+226.3%).
  • Quarterly Research & Development has moved between $245,779 (fiscal Q2 2024) and $2.72 million (fiscal Q3 2025) over five years.
  • Compared with a year earlier, Research & Development has declined for three straight quarters, with growth averaging 148.3% over the last eight quarters.
  • The best year-over-year quarter for Research & Development over five years was fiscal Q2 2025 (growth of 585.9%); the worst was fiscal Q2 2026 (a decline of 71.8%).
  • Per Business Quant data, LEXX's Research & Development in the three fiscal quarters before Q3 2026 was $475,388 (Q2 2026), $671,340 (Q1 2026) and $1.88 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 3.65 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.34 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -4.05 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 1.76 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 993.80 Mn
10 Lexaria Bioscience 3.39 Mn -12.26 Mn - 970,834.00
Historic Data

Historic Data

Download Data
DateValue
May 31, 2026 970,834.00
Feb 28, 2026 475,388.00
Nov 30, 2025 671,340.00
Aug 31, 2025 1.88 Mn
May 31, 2025 2.72 Mn
Feb 28, 2025 1.69 Mn
Nov 30, 2024 1.95 Mn
Aug 31, 2024 967,206.00
May 31, 2024 573,089.00
Feb 29, 2024 245,779.00
Nov 30, 2023 574,491.00
Aug 31, 2023 500,406.00
May 31, 2023 1.64 Mn
Feb 28, 2023 696,178.00
Nov 30, 2022 829,489.00
Aug 31, 2022 356,188.00
May 31, 2022 752,095.00
Feb 28, 2022 275,686.00
Nov 30, 2021 458,709.00
Aug 31, 2021 439,793.00
API Access

Lexaria Bioscience Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=LEXX&period=max&api_key=YOUR_API_KEY